Jhanelle E. Gray
Moffitt Cancer Center · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jhanelle E. Gray as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:02 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06219174 · Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)H. Lee Moffitt Cancer Center and Research Institute · suspended · Non Small Cell Lung Cancer, Lung Cancer · principal investigator
- Ph1/Ph2NCT03377023 · Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Non Small Cell Lung Cancer, Lung Cancer, Nonsmall Cell, Non Small Cell Lung Cancer Metastatic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Molecular MedicineP30CA076292 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2020 to 2026 · $47,589 awarded in 2026Same name and institution; not confirmed by an ID
- Exisulind for Chemoprevention of Lung CancerU01CA101222 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2007 · $1,000,956 awarded in 2007Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:02 UTC. The ranking covers the 200 most relevant of 54 PubMed records, and a shared surname and initials can bring in a namesake. All 54 on PubMed
- Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med · 20185,606 citationsRCR 203.9
- Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 20184,615 citationsRCR 168.8
- Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med · 20173,900 citationsRCR 133.1
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.N Engl J Med · 20202,543 citationsRCR 114.6
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med · 20182,335 citationsRCR 81.4
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.J Clin Oncol · 20221,268 citationsRCR 88.1
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol · 2020919 citationsRCR 38.3
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.J Clin Oncol · 2023685 citationsRCR 56.3
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol · 2018509 citationsRCR 15.5
- Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.J Thorac Oncol · 2021388 citationsRCR 21.2